Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $20 price target.
July 24, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Silence Therapeutics and maintained a $20 price target, indicating a positive outlook for the company.
The reiteration of an Overweight rating by Morgan Stanley indicates that they believe the stock will outperform its peers in the market. The maintained price target of $20 suggests that they believe the stock is currently undervalued. This is likely to have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100